Prophylactic Use of a Monoclonal Antibody (33B3.1) Directed Against Interleukin 2 Receptor Following Human Renal Transplantation
- 1 February 1988
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 11 (2) , 101-106
- https://doi.org/10.1016/s0272-6386(88)80189-6
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity.The Journal of Immunology, 1987
- PREVENTION OF REJECTION OF KIDNEY TRANSPLANTS BY MONOCLONAL ANTIBODY DIRECTED AGAINST INTERLEUKIN 2The Lancet, 1987
- Parameters of interaction of a novel monoclonal antibody (33B3.1) with the human IL2-Receptors: Interrelationship between 33B3.1, Anti-Tac, and IL2 binding sitesHuman Immunology, 1987
- Anti‐interleukin 2 receptor monoclonal antibodies. Respective role of epitope mapping and monoclonal antibody‐receptor interactions in their antagonist effects on interleukin 2‐dependent T cell growthEuropean Journal of Immunology, 1986
- Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice.The Journal of Experimental Medicine, 1985
- TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION WITH MONOCLONAL ANTI-T12 ANTIBODY1,2Transplantation, 1983
- T cell growth factor receptors. Quantitation, specificity, and biological relevanceThe Journal of Experimental Medicine, 1981